281 related articles for article (PubMed ID: 30185140)
1. Monitoring immunotherapy outcomes with circulating tumor DNA.
Goldberg SB; Patel AA
Immunotherapy; 2018 Sep; 10(12):1023-1025. PubMed ID: 30185140
[No Abstract] [Full Text] [Related]
2. Immunotherapy in non-small-cell lung cancer: potential predictors of response and new strategies to assess activity.
Rossi S; Castello A; Toschi L; Lopci E
Immunotherapy; 2018 Jul; 10(9):797-805. PubMed ID: 30008262
[TBL] [Abstract][Full Text] [Related]
3. [Biomarkers predictive of PD1/PD-L1 immunotherapy in non-small cell lung cancer].
Lupo A; Alifano M; Wislez M; Boulle G; Velut Y; Biton J; Cremer I; Goldwasser F; Leroy K; Damotte D
Rev Pneumol Clin; 2018 Oct; 74(5):339-350. PubMed ID: 30337201
[TBL] [Abstract][Full Text] [Related]
4. Combination Strategies on the Basis of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?
Qiao M; Jiang T; Ren S; Zhou C
Clin Lung Cancer; 2018 Jan; 19(1):1-11. PubMed ID: 28716463
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.
Soo RA; Lim SM; Syn NL; Teng R; Soong R; Mok TSK; Cho BC
Lung Cancer; 2018 Jan; 115():12-20. PubMed ID: 29290252
[TBL] [Abstract][Full Text] [Related]
6. Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies.
Sui H; Ma N; Wang Y; Li H; Liu X; Su Y; Yang J
J Immunol Res; 2018; 2018():6984948. PubMed ID: 30159341
[TBL] [Abstract][Full Text] [Related]
7. [Predictive biomarkers for immune checkpoint inhibitors in non-small-cell lung cancer].
Fu MJ; Zhou JY
Zhonghua Jie He He Hu Xi Za Zhi; 2020 Feb; 43(2):87-91. PubMed ID: 32062877
[TBL] [Abstract][Full Text] [Related]
8. New Immunotherapy and Lung Cancer.
Sánchez de Cos Escuín J
Arch Bronconeumol; 2017 Dec; 53(12):682-687. PubMed ID: 28823733
[TBL] [Abstract][Full Text] [Related]
9. Is immune checkpoint inhibition part of standard therapy for stage III non-small cell lung cancer?
Patel JD; Chmura SJ
Cancer; 2018 Jul; 124(14):2878-2880. PubMed ID: 29906817
[No Abstract] [Full Text] [Related]
10. The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly.
Sgambato A; Casaluce F; Gridelli C
Expert Opin Biol Ther; 2017 May; 17(5):565-571. PubMed ID: 28276698
[TBL] [Abstract][Full Text] [Related]
11. Advances in Immuno-Oncology: Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer-Introduction.
Socinski MA
Semin Oncol; 2015 Oct; 42 Suppl 2():S1-2. PubMed ID: 26477469
[No Abstract] [Full Text] [Related]
12. Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): Does biological rationale meet clinical needs?
Attili I; Passaro A; Pavan A; Conte P; De Marinis F; Bonanno L
Crit Rev Oncol Hematol; 2017 Nov; 119():30-39. PubMed ID: 29065983
[TBL] [Abstract][Full Text] [Related]
13. [Immune checkpoint inhibitors (antibodies to PD1 and PD-L1), a new therapeutic weapon against non-small cell bronchial carcinoma].
Berghmans T; Grigoriu B; Sculier JP; Meert AP
Rev Mal Respir; 2018 Feb; 35(2):197-205. PubMed ID: 29395567
[TBL] [Abstract][Full Text] [Related]
14. Understanding the Rationale for Immunotherapy in Non-Small Cell Lung Cancer.
Pennell NA
Semin Oncol; 2015 Oct; 42 Suppl 2():S3-10. PubMed ID: 26477472
[TBL] [Abstract][Full Text] [Related]
15. The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System.
Moon EK; Langer CJ; Albelda SM
Ann Am Thorac Soc; 2017 Aug; 14(8):1248-1260. PubMed ID: 28613923
[TBL] [Abstract][Full Text] [Related]
16. Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival.
Markowitz GJ; Havel LS; Crowley MJ; Ban Y; Lee SB; Thalappillil JS; Narula N; Bhinder B; Elemento O; Wong ST; Gao D; Altorki NK; Mittal V
JCI Insight; 2018 Jul; 3(13):. PubMed ID: 29997286
[TBL] [Abstract][Full Text] [Related]
17. Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade?
Furness AJ; Quezada SA; Peggs KS
Immunotherapy; 2016 Jun; 8(7):763-6. PubMed ID: 27349975
[No Abstract] [Full Text] [Related]
18. Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA.
Goldberg SB; Narayan A; Kole AJ; Decker RH; Teysir J; Carriero NJ; Lee A; Nemati R; Nath SK; Mane SM; Deng Y; Sukumar N; Zelterman D; Boffa DJ; Politi K; Gettinger SN; Wilson LD; Herbst RS; Patel AA
Clin Cancer Res; 2018 Apr; 24(8):1872-1880. PubMed ID: 29330207
[No Abstract] [Full Text] [Related]
19. Biomarkers for Immunotherapy.
Bustamante-Alvarez JG; Owen DH
Thorac Surg Clin; 2020 May; 30(2):207-214. PubMed ID: 32327179
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitors in lung cancer: an update.
Sullivan K; Preeshagul I; Budman D; Seetharamu N
Future Oncol; 2017 May; 13(11):955-959. PubMed ID: 28481150
[No Abstract] [Full Text] [Related]
[Next] [New Search]
